Unlock all Features See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Moodys
McKesson
Harvard Business School
Dow
Colorcon

Last Updated: November 27, 2022

CLINICAL TRIALS PROFILE FOR ABILIFY MAINTENA KIT


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Abilify Maintena Kit

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02146547 ↗ European Long-acting Antipsychotics in Schizophrenia Trial Completed UMC Utrecht Phase 4 2015-02-01 Schizophrenia is a chronic psychiatric illness with periods of remission and relapse. Patients vary in the frequency and severity of relapse, time until relapse and time in remission. Discontinuation of antipsychotic medication is by far the most important reason for relapse. A possible method to optimize medication adherence is to treat patients with long-term, depot medication rather than oral medication. However, despite its apparent "common sense" this approach has neither been universally accepted by practicing psychiatrists nor unequivocally demonstrated in clinical trials. Therefore, in this study we aim to investigate possible advantages of depot medication over oral antipsychotics in an independently designed and conducted, randomized, pragmatic trial.
NCT02472652 ↗ Aripiprazole, Abilify Maintena Collaborative Clinical Protocol Terminated Otsuka America Pharmaceutical Phase 4 2015-06-01 Sexual dysfunction is highly prevalent in schizophrenic patients, affecting up to 80% of men and women. Antipsychotic induced sexual side effects may be a barrier to treatment compliance. Antipsychotics such as Risperdal Consta and Invega Sustenna are known to have higher rates of causing prolactin elevations that may be implicated in sexual dysfunction. The basic premise of this study is to identify patients who believe they have experienced sexual dysfunction on Risperdal Consta or Invega Sustenna and switch to the alternative long acting injectable antipsychotic, Abilify Maintena which tends to lower prolactin levels. Measures of sexual sexual functioning using the self rated 5 item Arizona Sexual Experience Scale (ASEX) as the primary outcome measure will be made over a 3 month period to determine if such a switch is helpful.
NCT02472652 ↗ Aripiprazole, Abilify Maintena Collaborative Clinical Protocol Terminated Gazda, Thomas D., M.D., PC Phase 4 2015-06-01 Sexual dysfunction is highly prevalent in schizophrenic patients, affecting up to 80% of men and women. Antipsychotic induced sexual side effects may be a barrier to treatment compliance. Antipsychotics such as Risperdal Consta and Invega Sustenna are known to have higher rates of causing prolactin elevations that may be implicated in sexual dysfunction. The basic premise of this study is to identify patients who believe they have experienced sexual dysfunction on Risperdal Consta or Invega Sustenna and switch to the alternative long acting injectable antipsychotic, Abilify Maintena which tends to lower prolactin levels. Measures of sexual sexual functioning using the self rated 5 item Arizona Sexual Experience Scale (ASEX) as the primary outcome measure will be made over a 3 month period to determine if such a switch is helpful.
NCT02717130 ↗ Aripiprazole, Abilify Maintena Collaborative Clinical Protocol Terminated Burrell Behavioral Health N/A 2016-06-08 An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.
NCT02717130 ↗ Aripiprazole, Abilify Maintena Collaborative Clinical Protocol Terminated University of Missouri-Columbia N/A 2016-06-08 An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.
NCT02717130 ↗ Aripiprazole, Abilify Maintena Collaborative Clinical Protocol Terminated University of Missouri, Kansas City N/A 2016-06-08 An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.
NCT02717130 ↗ Aripiprazole, Abilify Maintena Collaborative Clinical Protocol Terminated Washington University School of Medicine N/A 2016-06-08 An Open-label, Multi-center, Longitudinal, Within-subject Comparison Study to Evaluate the Effects of Aripiprazole Once Monthly in Subjects with Schizophrenia on 30-, 90-, and 180- day Re-hospitalization Rates Following Hospital Discharge Compared with Retrospective Re-hospitalization Rates while on Oral Antipsychotic Medication.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Abilify Maintena Kit

Condition Name

Condition Name for Abilify Maintena Kit
Intervention Trials
Schizophrenia 7
Bipolar Disorder 1
LAI 1
Long-Acting Injection 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Abilify Maintena Kit
Intervention Trials
Schizophrenia 7
Bipolar Disorder 1
Disease 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Abilify Maintena Kit

Trials by Country

Trials by Country for Abilify Maintena Kit
Location Trials
United States 7
Korea, Republic of 7
Spain 4
Germany 4
United Kingdom 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Abilify Maintena Kit
Location Trials
Texas 1
California 1
Arkansas 1
Missouri 1
Nebraska 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Abilify Maintena Kit

Clinical Trial Phase

Clinical Trial Phase for Abilify Maintena Kit
Clinical Trial Phase Trials
Phase 4 5
Phase 1 3
N/A 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Abilify Maintena Kit
Clinical Trial Phase Trials
Completed 6
Terminated 2
Active, not recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Abilify Maintena Kit

Sponsor Name

Sponsor Name for Abilify Maintena Kit
Sponsor Trials
Otsuka Pharmaceutical Development & Commercialization, Inc. 2
Otsuka Beijing Research Institute 2
UMC Utrecht 1
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Abilify Maintena Kit
Sponsor Trials
Other 9
Industry 8
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Express Scripts
Dow
Moodys
Boehringer Ingelheim
Harvard Business School
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.